GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » EPS (Diluted)

SBMFF (Sino Biopharmaceutical) EPS (Diluted) : $0.02 (TTM As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical EPS (Diluted)?

Sino Biopharmaceutical's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was $0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

Sino Biopharmaceutical's EPS (Basic) for the six months ended in Jun. 2024 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

Sino Biopharmaceutical's EPS without NRI for the six months ended in Jun. 2024 was $0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

During the past 12 months, Sino Biopharmaceutical's average EPS without NRIGrowth Rate was 88.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -10.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sino Biopharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 108.00% per year. The lowest was -31.90% per year. And the median was 18.25% per year.


Sino Biopharmaceutical EPS (Diluted) Historical Data

The historical data trend for Sino Biopharmaceutical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical EPS (Diluted) Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.12 0.02 0.02

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 0.01 0.01

Competitive Comparison of Sino Biopharmaceutical's EPS (Diluted)

For the Biotechnology subindustry, Sino Biopharmaceutical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's PE Ratio falls into.



Sino Biopharmaceutical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sino Biopharmaceutical's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(326.593-0)/18575.080
=0.02

Sino Biopharmaceutical's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(415.891-0)/18408.302
=0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBMFF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sino Biopharmaceutical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

From GuruFocus

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Sino Biopharmaceutical Ltd's Dividend Analysis

By GuruFocus Research 06-11-2024